---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-034836"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2022-12-08T23:59:59+00:00"
generated_at: "2026-06-21T07:36:08.224127+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ensysce Biosciences prices $4.1M public offering of 2.9M shares and 5.8M warrants

## Summary
- Gross proceeds of ~$4.1M from offering of 2,900,000 shares (or pre-funded warrants) and 5,800,000 warrants at $1.40 combined price.
- Each warrant exercisable immediately at $1.40/share, expires 5 years from issuance.
- Underwriter (Lake Street Capital) granted 45-day option to purchase up to 342,000 additional shares and 870,000 warrants.
- 20% of gross proceeds to repay convertible notes; remainder for clinical development and working capital.
- Company directors and officers signed 90-day lock-up agreements restricting stock sales.

## SEC filing metadata
- accession: 0001493152-22-034836
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2022-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315222034836/0001493152-22-034836-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315222034836/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-034836
- JSON: https://secwatch.observer/filing/0001493152-22-034836.json
- Plain text: https://secwatch.observer/filing/0001493152-22-034836.txt

## Key facts
- Material Agreements
  Ensysce Biosciences, Inc. entered into Underwriting Agreement with Lake Street Capital Management, LLC valued at approximately $4.1 million (effective 2022-12-07).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Lake Street Capital Management, LLC
  - Value: approximately $4.1 million
  - Effective: 2022-12-07
  source text: On December 7, 2022, Ensysce Biosciences, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Lake Street Capital Management, LLC (the “ Underwriter ”), pursuant to which the Company agreed to issue and sell (i) 2,280,000 shares (the “ Firm Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), (ii) pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase 620,000 shares of Common Stock and (iii) warrants to purchase 5,800,000 shares of Common Stock (the “ Common Warrants ” and, collectively with the Pre-Funded Warrants, the “ Warrants ”) to the Underwriter in a public offering (the “ Offering ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315222034836/0001493152-22-034836-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.